Regenxbio Ownership
| RGNX Stock | USD 7.00 0.28 4.17% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 51 M | Current Value 51 M | Avarage Shares Outstanding 33.8 M | Quarterly Volatility 12.9 M |
Regenxbio |
Regenxbio Stock Ownership Analysis
About 88.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.3. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Regenxbio has Price/Earnings To Growth (PEG) ratio of 0.26. The entity recorded a loss per share of 4.59. The firm had not issued any dividends in recent years. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Regenxbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 372 people. To find out more about Regenxbio contact Kenneth Mills at 240 552 8181 or learn more at https://www.regenxbio.com.Regenxbio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regenxbio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regenxbio backward and forwards among themselves. Regenxbio's institutional investor refers to the entity that pools money to purchase Regenxbio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-12-31 | 856.6 K | Goldman Sachs Group Inc | 2024-12-31 | 756.2 K | Citadel Advisors Llc | 2024-12-31 | 585.4 K | Avidity Partners Management Lp | 2024-12-31 | 532 K | Adage Capital Partners Gp Llc | 2024-12-31 | 500 K | Northern Trust Corp | 2024-12-31 | 465.3 K | Norges Bank | 2024-12-31 | 449.4 K | Sonic Gp Llc | 2024-12-31 | 403.1 K | Two Sigma Investments Llc | 2024-12-31 | 389.4 K | Blackrock Inc | 2024-12-31 | 5.5 M | Redmile Group, Llc | 2024-12-31 | 4.8 M |
Regenxbio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regenxbio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regenxbio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regenxbio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Regenxbio's latest congressional trading
Congressional trading in companies like Regenxbio, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Regenxbio by those in governmental positions are based on the same information available to the general public.
| 2019-11-14 | Representative Peter Welch | Acquired Under $15K | Verify |
Regenxbio Outstanding Bonds
Regenxbio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regenxbio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regenxbio bonds can be classified according to their maturity, which is the date when Regenxbio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Regenxbio Corporate Filings
8K | 13th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify | |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.